Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 105

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 105
---
Sales DiscountsTotalBalance at December 31, 2023$57,290 $96,984 $10,719 $164,993 Provision related to:Current year sales10,774 200,930 34,119 245,823 Prior year sales(4,055)(1,923)(6)(5,984)Total provision6,719 199,007 34,113 239,839 Less: Actual payments/credits(5,472)(179,409)(31,300)(216,181)Balance at June 30, 2024$58,537 $116,582 $13,532 $188,651 

Accrued Product Returns and Rebates

The accrued product returns balance decreased to $46.0 million as of June 30, 2025 from $58.5 million as of June 30, 2024. This decrease was primarily due to the $12.5 million of estimated provision for product returns related to prior year sales. The majority of the provision for product returns related to prior year sales is attributable to Qelbree, reflecting favorable actual returns experienced in 2025 for Qelbree. As a result, the Company changed its estimated provision for product returns based on the most recent experience.

The accrued product rebates balance increased to $134.9 million as of June 30, 2025 from $116.6 million as of June 30, 2024 primarily due to timing of payments associated with government programs. 

Provision for Product Returns and Rebates

The provision for product returns decreased to $5.2 million for the six months ended June 30, 2025 from $6.7 million for the six months ended June 30, 2024. The decrease was primarily due to the aforementioned reduction of $12.5 million of estimated provision for product returns related to prior year sales. 

The provision for product rebates increased to $207.5 million for six months ended June 30, 2025 from $199.0 million for the six months ended June 30, 2024. The increase was primarily attributable to higher Qelbree sales and unfavorability in government programs as a result of product price increases in Q1 2025.

Royalty, Licensing and Other Revenues

Royalty, licensing and other revenues were $7.5 million and $5.8 million for the three months ended June